ArticleJournal of thoracic disease2025
Optimizing primary tumor resection decisions for non-small cell lung cancer patients with brain metastases: analysis based on the SEER database and development and external validation of predictive models.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain metastases (BM) in non-small cell lung cancer (NSCLC) are associated with poor prognosis, and the role of primary tumor resection (PTR) remains controversial. This study aims to evaluate the role of PTR in NSCLC patients with BM and develop a predictive tool to identify optimal surgical candidates. Methods: We analyzed data from 608 patients who underwent PTR and 18,529 patients who did not, sourced from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (PSM), a statistical method to balance baseline characteristics between treatment groups, was performed to minimize selection bias. We utilized Kaplan-Meier (KM) survival analysis, Cox regression analysis, and PSM to assess the impact of PTR on the prognosis of BM patients. Logistic regression analysis was performed to identify and quantify the clinical factors that influence the benefits of PTR in BM patients, which informed the development of a predictive model. The model's predictive accuracy and clinical applicability were evaluated using the Concordance index (C-index), F1 score, receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA), with 42 patients from Fujian Provincial Hospital serving as the external validation cohort. Results: KM survival analysis revealed significant survival differences between the PTR and non-PTR groups, both before and after PSM, with median survival times of 15 and 7 months, respectively. PTR was identified as an independent clinical factor affecting the prognosis of BM patients. In the training set, the C-index for the model was 0.7857 [95% confidence interval (CI): 0.7387-0.8327]. In the validation set, the C-index was 0.7441 (95% CI: 0.6674-0.8208), and in the external validation set, it was 0.7759 (95% CI: 0.5855-0.9662). The F1 score of the predictive model was 0.7667. Analyses of the ROC curve, calibration curve, and DCA indicated that the model exhibits strong accuracy and clinical applicability. Conclusions: This study indicated that PTR can enhance the prognosis of NSCLC patients with BM and also establishes an effective screening tool for quantifying the likelihood of patient benefiting from PTR treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.